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ABSTRACT: Here, we describe a strategy for the rapid
preparation of pure positional isomers of complex N-glycans to
complement an existing array comprising a larger number of N-
glycans and smaller glycan structures. The expanded array was then
employed to study context-dependent binding of structural glycan
fragments by monoclonal antibodies and C-type lectins. A partial
enzymatic elongation of semiprotected core structures was
combined with the protecting-group-aided separation of positional
isomers by preparative HPLC. This methodology, which avoids the
laborious chemical diﬀerentiation of antennae, was employed for
the preparation of eight biantennary N-glycans with Galβ1,4GlcNAc (LN), GalNAcβ1,4GlcNAc (LDN), and GalNAcβ1,4-
[Fucα1,3]GlcNAc (LDNF) motifs presented on either one or both antennae. Screening of the binding speciﬁcities of three anti-
LeX monoclonal IgM antibodies raised against S. mansoni glycans and three C-type lectin receptors of the innate immune
system, namely DC-SIGN, DC-SIGNR, and LSECtin, revealed a surprising context-dependent ﬁne speciﬁcity for the
recognition of the glycan motifs. Moreover, we observed a striking selection of one individual positional isomer over the other
by the C-type lectins tested, underscoring the biological relevance of the structural context of glycan elements in molecular
recognition.
N-glycosylation is a very common modiﬁcation of themajority of eukaryotic proteins. N-glycans have important
intracellular functions in protein folding, targeting, and
degradation and play extracellular roles in protein stability,
antigenicity, and molecular binding and signaling in cellular
communication.1−3 The heterogeneity generally observed in
protein glycosylation is a consequence of the nontemplate
nature of glycan biosynthesis that is controlled by expression
levels of glycosyltransferases and transporter proteins, nucleo-
tide sugar donor concentrations, and protein−protein and
protein−carbohydrate interactions around the glycosylation
sites. Hence, glycan proﬁles are not only species-, tissue-, cell-, or
protein-speciﬁc but often altered under pathological or changing
physiological conditions, underscoring their potential as disease
markers.4
The structural heterogeneity of complex N-glycans is largely
due to the variable enzymatic elongation of terminal N-
acetylglucosamine (GlcNAc) moieties with galactose, sialic
acid, and fucose residues on bi-, tri-, and tetra-antennary glycans.
The majority of N-glycan structures found in nature have
nonidentical antennae, giving rise to isomeric and structural
variations in the terminal motifs that form speciﬁc ligands for
glycan-binding proteins.5−7
Molecular recognition processes based on carbohydrate−
protein interactions have been found to mediate a plethora of
biological processes including cell adhesion, cell development,
protein traﬃcking, or the diﬀerentiation of self-and nonself by
the immune system.4,8 The usually weak monovalent
interactions between carbohydrates and proteins are reinforced
by a multivalent presentation of glycans on cell surfaces and
through multimerization of receptors and glycan binding
domains. Therewith, aﬃnities can be increased up to 6 orders
of magnitude, leading to binding strengths comparable to those
of protein−protein interactions.9,10 On the molecular level,
carbohydrate−protein interactions are stabilized by hydrogen
and water mediated hydrogen bonding, calcium coordination,
hydrophobic interactions between aliphatic amino acid side
chains with CH groups, and CH−π interactions between
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aromatic amino acid side chains and sugar residues.11−13
Ultimately, glycan motif presentation, e.g., by glycan clustering,
as repeating units in polysaccharides or on the antennae glycans
of secreted glycoproteins, can inﬂuence the strength and
speciﬁcity of glycan protein interactions.8,10
In relation to pathogen recognition and the discrimination
between self and nonself on the basis of glycan determinants,
two important classes of carbohydrate binding proteins are
antiglycan antibodies and lectins of the innate immune system.
Immune responses to viral, bacterial, and parasitic infections are
often orchestrated by glycan-induced molecular mechanisms.
In various parasitic worm infections, including the major
human disease schistosomiasis, the antibody response is
dominated by antibodies directed against antigenic glycans
expressed on the parasite surface or on secreted glycoprotein
antigens.14 Knowledge of the exact binding speciﬁcities of these
(monoclonal) antibodies is highly relevant for the development
of diagnostic assays, in imaging, and in the development of
glycan-targeting therapeutics.
One important class of mammalian glycan-binding receptors
of the innate immune system is the C-type lectin receptors
(CLRs). CLRs are pattern recognition receptors (PRRs) located
on immune cells and involved in the recognition and uptake of
both self and nonself glycoconjugates. Beyond their important
functions in pathogen and/or antigen recognition and uptake,
some CLRs are multifunctional receptors mediating cell
adhesion, glycoprotein clearance, or further signaling
events.10,15 With few exceptions, CLRs with sugar binding
aﬃnity share a common fold for their carbohydrate binding
domain and a well-deﬁned primary sugar-binding site that
involves the coordination of calcium ions.15 On the basis of the
speciﬁcity of their carbohydrate binding domain (CRD), CLRs
are roughly grouped into mannose/fucose and galactose/
GlcNAc binding receptors, but the ﬁne speciﬁcity and additional
aﬃnity is gained through binding of oligosaccharides to an
extended binding domain or via secondary binding sites.15,16
In this study, we have explored the inﬂuence of the structural
context of N-glycan antenna ligands for binding of three anti-
Lewis X antibodies directed against S. mansoni glycans and three
C-type lectins, DC-SIGN, DC-SIGNR, and LSECtin.17,18 DC-
SIGN and DC-SIGNR are closely related CLRs that bind Ebola,
hepatitis C, and human immune deﬁciency viruses via high
mannose and complex type N-glycans of the viral surface
proteins. While DC-SIGN induces speciﬁc immune responses
upon interaction with numerous pathogens, DC-SIGNR in
contrast seems to be only an adhesion receptor.17,19 Both
receptors have also been reported to enhance trans-infection of
T-cells even at low viral loading by capture and eﬃcient surface
presentation of HIV to CD4 presenting cells.20,21 L-SECtin
recognizes Ebola virus via complex-type N-glycans22 of the viral
envelope protein, as well as West Nile ﬁlovirus and SARS
coronavirus,23 but not HIV or hepatitis C virus.24 It also
interacts with activated T-cells.25
Targeting antigen to densely expressed dendritic cell
receptors such as DC-SIGN is an attractive strategy for vaccine
eﬃcacy improvement and immunotherapy26 and has been
achieved both with antilectin antibodies and with glycans
recognized by the targeted lectin receptor.27−30 A lack of
speciﬁcity due to an overlap in glycan binding speciﬁcities of
lectin receptors can be problematic for dendritic cell targeting
approaches, especially if various receptors with opposing
functions are responsive. The identiﬁcation of high aﬃnity and
selective ligands that speciﬁcally target a single receptor on
dendritic cells is an active area of research not only for
immunotherapy and vaccine development but also for under-
standing lectin receptor function in antigen recognition, uptake,
and processing. Previous glycan array proﬁling experiments have
shown that DC-SIGN and DC-SIGNR both recognize
Manα1,2Man residues, preferentially in high mannose type
glycans, but that only DC-SIGN shows aﬃnity to blood group
antigens by binding to Fucα1,3GlcNAc and Fucα1,4GlcNAc
residues.17,31,31 Recently, Guo et al. have shown diﬀerentiated
binding patterns of tetravalent DC-SIGN R and DC-SIGN as a
function of the mannose residue density on glycan function-
alized quantum dots. While DC-SIGN bound eﬃciently to
quantum dots displaying mannose residues at high density, the
spatially diﬀerently oriented DC-SIGNR CRDs could not
engage in a suﬃcient number of contacts for strong binding.32
Other screening eﬀorts have also shown strong binding of DC-
SIGN to biantennary GlcNAc terminating glycans, which is
however completely lost in the presence of a core α1,2 xylose
residue.33
All binding studies in this work were performed on an
expanded version of our existing synthetic glycan array. It
includes a large number of N-glycans reﬂecting a signiﬁcant part
of the structural heterogeneity found for antennae type and
number, core modiﬁcations, and terminal sugar residues and an
additional collection of smaller glycan fragments and blood
group antigens.33,34 For this study, we broadened our glycan
array with a series of complex biantennary N-glycans presenting
Galβ1,4GlcNAc (LacNAc), GalNAcβ1,4GlcNAc (LDN), and
GalNAcβ1,4[Fucα1,3]GlcNAc (LDNF)motifs on either one or
both antennae (Figures 2 and 3). In 2012, Benevides et al.
observed the unusual speciﬁcity of a lectin from the legume
Platypodium elegans for asymmetrically branched glycans.35 A
year later, the Boons group presented a strategy for the synthesis
of N-glycans with diﬀerentiated antennae and found signiﬁcant
diﬀerences in the binding aﬃnities of some antennae isomers to
certain plant lectins and to hemagglutinins involved in inﬂuenza
virus binding. This work suggested a role for positional isomers
in molecular recognition processes.36 Since then, other reports
of diﬀerential binding patterns of asymmetrically branched
glycans and strategies for their synthesis have appeared.37−39
The chemo-enzymatic synthesis of asymmetrically extended
complex multiantennary glycan isomers was ﬁrst reported by the
Boons group, based on an orthogonally protected central
pentasaccharide scaﬀold and on a set of partially protected
advanced glycosyl donors.36 Subsequent enzymatic glycosyla-
tions elongated only fully deprotected antennae residues while
acetate protected terminal sugars remained unchanged.
However, this elegant approach suﬀered from incomplete
enzymatic reactions, leading to compound mixtures that were
arduous to separate.40 Moreover, an elaborate chemical
synthesis has to be accomplished for every underlying scaﬀold
structure. This prompted us to seek an alternative approach for
the preparation of N-glycan positional isomers.
Recently, we have developed PADS, the Protecting-group-
Aided Detection and Separation of glycans, as a very robust
methodology to quickly prepare libraries of all enzymatically
accessible positional isomers from just a handful of multi-
antennary basic glycan scaﬀolds.38 LDN and LDNF constitute
CLR ligands that are very selectively expressed on mammalian
N-glycoproteins41 but that are highly abundant for instance in
helminth parasites, including S. mansoni, one of the most
signiﬁcant worm parasites of humans.We studied the interaction
of positional N-glycan isomers with several antiglycan
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monoclonal antibodies and human C-type lectins involved in
pathogen and self recognition. These new binding data support
the idea of isomer-speciﬁc roles in carbohydrate mediated
molecular recognition.
■ RESULTS AND DISCUSSION
Synthesis. Enzymatic reactions toward the preparation of
biantennary N-glycans presenting LDN and LDNF motifs were
performed on the two partially benzylated glycan scaﬀolds 1 and
Scheme 1. Chemical Synthesis of Biantennary N-Glycan 1: (a) 10% TMSOTf, CH2Cl2, m.s., −20°C, 76%; (b) BF3·OEt2, EtSH,
CH2Cl2, 79%; (c) 4, 10%TMSOTf, CH2Cl2, m.s.,−45°C, 52%; (d, i) NH2(CH2)2NH2, nBuOH; (ii) Ac2O, pyridine; (iii) NaOMe,
MeOH; Below: Pictogram Presentation of Semiprotected Glycans 1 and 2 with Benzyl Protected Monosaccharide Residues
Boxed in Light Blue
Figure 1. Galactosylation reaction of 1 and 2 and the corresponding puriﬁcation chromatograms. (a) GalT, UDP-Gal, HEPES 50 mM at pH 8.5,
MnCl2 10 mM, 37 °C. Galactosylation reaction of 1, product distribution: 8, 26.5%; 9, 22.3%; 10, 25.4%; 1, 25.8%. Galactosylation reaction of 2,
product distribution: 11, 44.1%; 12, 12.4%, 13, 29.2%, 2, 14.3%.
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2, with compound 2 presenting an additional benzyl group at C2
of the central mannose residue. The synthesis of both scaﬀolds 1
and 242 follows a [3 + 2 + 2] building block approach and is
described in detail in the Methods section (see also Scheme 1).
Enzymatic Synthesis. The enzymatic extension of 1 and 2
synthesis to glycans presenting terminal LN (N-acetyl lactos-
amine), LDN, and LDNF moieties was carried out with a
recombinant bovine milk galactosyltransferase (GalT), a mutant
of bovine milk galactosyltransferase with GalNAc-transferase
(GalNAcT) activity,43 and a Lewis X type fucosyltransferase
(FucT) fromC. elegans. The presence of benzyl groups distant to
the acceptor site had little or no inﬂuence on the outcome of the
enzymatic reactions. To ensure a largely equimolar product
distribution, we monitored the enzymatic reaction by UPLC-
MS and carefully adjusted the substrate concentration, the
incubation time, and the amounts of both added enzyme and
nucleotide donor UDP-Galactose. Tuning of reaction con-
ditions including time, enzyme, and donor concentrations
aﬀorded both regioisomers 8 and 9, alongside the bis-elongated
product 10 and the starting glycan 1 in nearly equimolar
amounts, in line with the known indiscriminate action of the
enzyme on the 3- and 6-arms of biantennaryN-glycans44 (Figure
1).
For the galactosylation of 2, however, with an additional 2-O-
benzyl group in the central mannose residue (Scheme 1), we
observed the preferred formation of one regio-isomer over the
other (Figure 1). Separation of the reaction components by
preparative HPLC and structural assignment of both isomers by
NMR revealed the 3-arm as the preferred branch for
galactosylation (11, 44.1%). The added steric bulk conveyed
by the benzyl group apparently gave rise to an unfavorable
interaction with the enzyme for the elongation of the GlcNAc
residue on the 6-arm. Consequently, only 12.4% of the 6-isomer
12 was formed. This protecting group induced selectivity was
surprising, and a more systematic investigation of the steric
eﬀects of residual protecting groups as a means of modulating
the selectivity of glycosyltransferases and glycosidases is
currently underway in our lab.
For the rapid preparation of near equimolar amounts of all
regio-isomers, however, the 2-O-benzyl-protected glycan 2
seemed less suited and was therefore abandoned as a scaﬀold
for further enzymatic reactions. For the preparation of terminal
GalNAc glycans, we incubated glycan 1 with UDP-GalNAc and
GalNAcT and carefully adjusted the amount of enzyme, of
nucleotide donor and the reaction time to produce similar
amounts of both regioisomers 14 and 15, starting material 1, and
bis-glycosylated product 16, which were easily separated by
preparative HPLC (Figure 2). Benzyl protected aliquots of 14,
15, and 16 were subjected to further enzymatic derivatization
with a Lewis type fucosyltransferase to produce the LDNF
immunogenic element on one or both arms of the biantennary
N-glycan. Compounds 14 and 15 were incubated with CeFUT6
and GDP-fucose and the enzymatic conversion monitored for
each reaction by MALDI-TOF mass spectrometry (Figure 3).
After 20 h of incubation, around 50% of isomer 14 had reacted,
and after 48 h, the fucosylation had reached completion. The
Figure 2. Enzymatic N-acetyl-galactosamination of 1. (a) GalT mutant, UDP-GalNAc, HEPES 50 mM pH 8.5, MnCl2 10 mM, 37 °C. Product
distribution: 14, 24.4%; 15, 27.5%, 16, 27.6%, 1, 20.5%.
Figure 3.MALDI-TOF MS spectra of the fucosylation of 14 (left) and 15 (right) after 20 h and 48 h, respectively. (a) GDP-Fuc, CeFUT6, MES 40
mM, MnCl2 10 mM.
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isomer 15 with the GalNAc residue on the 6-arm reacted
substantially slower, showing only 10% conversion to the
fucosylated product 18 after 20 h (Figure 3). The reaction was
left for 48 h until no further conversion to 18 was observed by
MALDI-TOF MS, and the unreacted starting material was
removed by preparative HPLC.
Treatment of the glycan 16 with CeFUT6, an α-1,3
fucosyltransferase that catalyzes the addition of a fucose residue
at the distal GlcNAc of the chiotobiose core in C. elegans N-
glycans45 and which also shows activity toward terminal LN and
LDN residues,46 provided a mixture of regioiomers 19 and 20
and bis-glycosylated glycan 21. Although the enzyme adds
fucose on GalNAc residues of both antennae, the chromato-
graphic proﬁle (Figure 4) suggests preferential glycosylation of
the 3-arm prior to addition on the 6-arm, a selectivity which we
believe has not been described before. Even after 5 days of
incubation with CeFUT6 and the GDP-fucose donor and after
most starting glycan had been consumed, only trace amounts of
the 6-isomer 20 (1.7%) were formed. To gain access to useful
amounts of region-isomer 20, we treated the monofucosylated
glycan 18 with GalNAcT and UDP-GalNAc.
After puriﬁcation by semipreparative HPLC, compounds 8−
10, 14−15, and 17−21 groups were deprotected by Pd/C
catalyzed continuous ﬂow hydrogenation (for details, refer to
the SI) providing eight new positional isomers 22−29 with LN,
LDN, and LDNF structural elements (Figure 5), which were
included in our N-glycan microarray alongside our existing
collection of 126 synthetic glycans onto NHS-activated glass
microarray slides (see SI for all structures included on the glycan
array).33
Carbohydrate Fine Speciﬁcity of Anti-LeX Antibodies
Derived from S. mansoni InfectedMice. Printed arrays were
ﬁrst used to study the glycan binding speciﬁcities of monoclonal
antibodies produced by hybridomas generated from the spleen
cells of S. mansoni infected mice.47,48 Schistosomiasis is an
infectious disease caused by blood ﬂukes of the Schistosoma
genus that aﬀects more than 200 million people worldwide.49 S.
mansoni parasites are highly glycosylated during all devel-
opmental stages and present a structurally rich variety of glycans
including fucosylated LN and LDN motifs on their cell surface
and secreted glycoproteins. Both innate and adaptive immune
responses toward schistosome glycans are generated upon
infection in humans, including the formation of antiglycan
antibodies.48,50 Several years ago, Remoortere et al. studied the
glycan binding speciﬁcities of a library of 188mAbs derived from
Schistosoma-infected or immunizedmice employing a number of
small synthetic glycan conjugates.49,51,52 Antibodies were
grouped by binding speciﬁcity for Lex, LDN, and LDNF
epitopes, found in diﬀerent developmental stages of S. mansoni
and in addition classiﬁed for distinguishing monomeric from
polymeric epitope presentation. The antibodies were then
employed to visualize the spatial distribution of glycan epitopes
in various stages of the parasite by immunoﬂuorescence
assays.49,53 Here, we have screened a selection of mAbs known
to bind Lex epitopes to assess the eﬀect of epitope presentation
within the context of a larger N-glycan by glycan array
methodology. Printed glycan arrays were incubated with diluted
antibody solutions, and binding was detected by incubation with
a ﬂuorescently labeled secondary antimouse immunoglobulin
antibody. Figure 6 shows the speciﬁcities of three LeX binding
monoclonal IgM antibodies for glycans presenting the LeX
epitope. The mAb 128−4F9 recognizes Lex only as the free
nonextended trisaccharide epitope, but not within the context of
a larger N-glycan as neither GL32−GL36, GL38, GL82, nor
GL92 presenting the same epitope on the 3- and/or the 6-arm
are bound. In contrast, the mAb 99−1G3 recognizes LeX
Figure 4. α-1,3-Fucosylation of compound 16. (a) GDP-Fuc, CeFUT6,
MES 40 mM, MnCl2 at 10 mM. Chromatogram of the reaction after 48
and 120 h, respectively. Product distribution after 48 h: 19, 55.6%; 20,
4.6%; 21, 11.8%; 16, 28.0%. After 120 h: 19, 55.8%; 20, 1.7%; 21,
35.7%; 16, 6.8%.
Figure 5. Pictogram representation of the eight newly synthesized positional LN, LDN, and LDNF isomers.
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exclusively on the 3-arm of the two core xylosylated glycans
(GL32, GL33), while other compounds presenting the epitope
in a spatially diﬀerent manner, including the free epitope, are not
bound. The third Lex binding mAb 291−4D10 displays yet
another speciﬁc binding proﬁle as it recognizes both the free
epitope and a structure presenting the epitope on the 6-arm of a
core-xylosylated N-glycan (GL34). Compounds presenting the
epitope on the 3-arm (GL35) or bis-functionalized compounds,
GL36 andGL38, were however not bound at all by 291−4D10.
A rationale for this highly speciﬁc context-dependent binding is
diﬃcult to provide without additional structural information
regarding the carbohydrate antibody complex. However, a
possible explanation for the observed ﬁne-speciﬁcity of these
mAbs would be that their binding site extends beyond the Lex
Figure 6. Glycan binding proﬁle of S. mansoni-related monoclonal IgM antibodies 128−4F9, 99−1G3, and 291−4D10 toward Lex containing
structures. RFU values were analyzed after incubation with Alexa Fluor-555 antimouse IgM. Each histogram represents the mean RFU values for four
spots with the SD of the mean.
Figure 7. Glycan binding proﬁle of DC-SIGN ECD and DC-SIGNR ECD. (A) Schematic representation of glycan structures binding to DC-SIGN
and/or DC-SIGNR grouped by structure: (a) high mannose related structures, (b) hybrid N-glycans, (c) complex GlcNAc terminating N-glycans, (d)
galactose containing N-glycans. (e) LDN containing N-glycans, (f) Lex containing N-glycans and Ley, (g) LDNF containing N-glycans. (B)
Histograms representing the % RFU values for DC-SIGN and DC-SIGNR binding. (C) Comparison of %RFU values of monogalactosylated and N-
glycans with terminal single GalNAc residues in DC-SIGN and DC-SIGNR binding.
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trisaccharide itself. The mAbs 99−1G3 and 291−4D10 appear
to be selective for the α3- and α6-arms of core xylosylated
glycans, respectively, indicating that the mannose residue and
the context of the trimannosyl core may take part in the mAb−
glycan interactions. The observed speciﬁcity might also be the
result of compound exclusion due to sterical clashes of antennae
residues with the lectin rather than binding of a larger epitope via
an extended binding groove. In contrast, 128−4F9 may prefer a
more freely accessible Lex motif such as in the context of the
synthetic trisaccharide-linker conjugate. Crystallographic stud-
ies54 indicated that glycan-binding pockets of Fab fragments can
indeed accommodate oligosaccharides larger than a trisacchar-
ide, including a linear trimer of Lex. Interestingly, an at that time
unspeciﬁed diﬀerence in the binding of LeX-containing N-
glycans between 99 and 1G3 and 291−4D10 was observed
earlier using a glycan microarray of naturally occurring glycans
isolated from S. mansoni.55 N-glycans containing a single LeX
antenna were bound by 291−4D10, but not by 99−1G3,
suggesting that the so far unspeciﬁed location of the LeX motif in
these cercarial glycans was on the α6-arm rather than the α3-
arm. Therefore, unraveling the ﬁne speciﬁcity of antiglycan
mAbs by deﬁned synthetic glycan arrays is helpful in deﬁning
isomeric and asymmetric glycan structures from natural sources.
The exquisite antiglycan speciﬁcity of some monoclonal
antibodies found in this study highlights the importance of
epitope selection and presentation and could have important
consequences, e.g., in immunoassays employing natural or
synthetic glycan antigens such as those that detect allergen-
directed IgEs.56
Screening of the Carbohydrate Binding Speciﬁcity of
C-Type Lectin Receptors. Here, printed arrays including the
novel structures 22−29 were used to screen the C-type lectins
DC-SIGN, DC-SIGNR, and LSECtin. Both DC-SIGN and DC-
SIGNR extracellular domains (ECDs) were incubated on our
array seeking ligands with selectivity for one of these two closely
related lectins. Figure 7 shows strong binding of DC-SIGN to
hybrid (GL54−GL57) and complex type glycans (GL48−
GL50) and N-glycans presenting Lex epitopes (GL82 and
GL92). One of the most strongly bound glycans in our
collection was, as previously shown, the complex type
biantennary glycan GL48.33 We also observed a signiﬁcant
binding to the biantennary glycan monogalactosylated on the 6-
arm (GL127) but not to the positional isomer galactosylated on
the 3-arm (GL126). A similar behavior was observed for N-
glycans with a single terminal N-acetylgalactosamine (GalNAc)
residue (GL128 andGL129). Incubation of DC-SIGNR on the
same arrays gave a slightly diﬀerent picture than DC-SIGN
(Figure 7). The strongest binding glycan was the high mannose
glycan GL45 with an atypical non-natural branching pattern
presenting the Manα1−3(Manα1−6Man) trisaccharide on
both 3 and 6 arms. GL45 was less strongly bound by DC-
SIGN. Even more interestingly, we observed opposite binding
behavior of DC-SIGNR and DC-SIGN toward the monoga-
lactose and mono-GalNAc positional isomers. Both galactosy-
lated and GalNAc-terminating glycansGL126 andGL128 were
speciﬁcally recognized by DC-SIGNR, while the corresponding
positional isomers GL127 and GL129 were bound with far
lower aﬃnity.
Finally, we looked at the carbohydrate binding proﬁle of the
C-type lectin L-SECtin CRD to our glycan array. L-SECtin is
widely expressed in lymph node and liver endothelial tissue,
peripheral blood, and on macrophages.18 Its carbohydrate
binding speciﬁcities have not been studied in much detail yet. A
report fromDominguez-Soto et al.mentions binding to GlcNAc
functionalized sepharose but not to mannan or GalNAc
analogues.18 A later published binding proﬁle to an array of
300 glycans showed high aﬃnity of the CRD to GlcNAcβ-1,2-
Man containing glycan fragments, while fucosylated and
mannosylated glycans were only identiﬁed as low aﬃnity
binders at very high receptor concentrations.22 Our results
indicate an even higher selectivity of L-SECtin CRD for
GlcNAc1,2-Man residues on the 3-arm of the complex and
hybrid N-glycans. An additional GlcNAc residue in position C4
inhibited binding (structures GL47, Figure 8). The same
GlcNAc1,2-Man disaccharide presented on the 6-arm of di-, tri-,
or tetra-antennary complex N-glycans was bound to a far lesser
extent (structures GL48, GL51, GL52). An additional capping
with galactose on the 3-arm (GL126) completely abolishes the
low binding of GlcNAc1,2-Man residues on the 6-arm. An N-
acetylgalactosamine cap on the same arm is not as eﬃcient in
inhibiting this interaction (structures GL128 and GL129). The
striking observation comes again from the diﬀerential
interaction of LSECtin toward two positional isomers GL126
and GL127 where a galactose is capping the 3- and 6-arm,
respectively. Similar behavior, albeit to a lesser extent, can be
observed with two other couples of positional isomers with an
LDN (GL128,GL129) motif or LDNFmotif (GL130,GL131)
present on the 3- and 6-arms, respectively. It is yet another
example for the context speciﬁc binding of a well-deﬁned
structural element. This highlights the biochemical relevance of
truncated or incompletely extended structures here for the
Figure 8. (A) Cy3-labeled L-SECtin CRD binding proﬁle toward selected N-glycan structures. Each histogram represents the mean RFU values for
four spots with the SD of the mean. (B) Preferred epitope found in complex and hybrid N-glycans for binding toward L-SECtin CRD.
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molecular recognition of glycans and glycoproteins by C-type
lectin immune receptors.
The binding data of L-SECtin can be resumed in the preferred
ligand GlcNAcβ1,2Manα1,3Man. Substitution of this structural
element with core xylose is tolerated, while capping with
galactose or additional branching with β1−4GlcNAc completely
inhibits binding. Capping with GalNAc on the 3-arm or
branching with β1−6GlcNAc on the 6-arm does not aﬀect the
moderate binding observed for structures presenting a
GlcNAcβ1,2Man residue on the 6-arm (structures GL48,
GL51, GL52).
■ CONCLUSIONS
We and others have reported a growing number of examples
where previously deﬁned minimal ligand structures are diﬀer-
entially recognized by antibodies, lectins, and glycosyltrans-
ferases when presented in diﬀerent structural contexts. This
common feature in glycan recognition can be explained by the
existence of more extended binding domains that can
accommodate larger structural elements than previously
thought. Another possible explanation could be the existence
of diﬀerent binding modes between an oligosaccharide and
protein binding domain, with at times exquisite selectivity as
suggested by some of our positional isomer selective binding
data. The ever more extended structural annotation of glycan
structures with simple pictograms that neglect glycosidic
binding information might nurture the misconception of
symmetrically equivalent antennae branches in N-glycans
similar to a dendrimer. Detailed structural analysis, e.g., by
NMR has shown large diﬀerences in the accessibility and the
three-dimensional orientation for the diﬀerent arms of the same
N-glycan backbone in line with the diﬀerent connectivity of
monosaccharide residues. The structural asymmetry between
antennae can now be visualized by NMR by attaching a
paramagnetic lanthanide tag to the anomeric position of a
multiantennary glycan. The induced pseudo-contact shifts
decrease with the distance to the paramagnetic metal and
provide spectral separation of peaks for the same residues
present on diﬀerent antennae.57 The identiﬁcation of a pair of
positional N-glycan isomers that selectively bind to DC-SIGN
and DC-SIGNR was an unexpected but welcome ﬁnding, which
opens the door to further improvement on the selectivity and
aﬃnity of the identiﬁed ligands by medicinal chemistry
approaches. Likewise, the discovery of the monogalactosylated
N-glycan GL127 as a very strong binder of L-SECtin while the
isomeric glycan does not show any binding requires further
structural analysis, e.g., by NMR. Additional screening of other
human lectins will show if this lead structure could eventually
become a selective probe for targeting this important lectin
involved in pathogen recognition and T-cell activation. Finally,
the diﬀerences we observed for mAbs binding the Lex epitope
indicates that not only lectins but also the adaptive immune
system (antibodies) can diﬀerentiate glycan motifs presented in
diﬀerent contexts.
■ METHODS
Chemical Synthesis of Semiprotected N-Glycan Precursors 1
and 2. Brieﬂy, 1 was prepared by the sequential glycosylation of
trisaccharide 3 with the disaccharide donor 4 on the central mannose
residue. Glycosylation at position C3 under TMSOTf promotion
provided pentasaccharide 5 in 76% yield. The Bn-acetal was
subsequently removed by transacetalization with thioethanol and
BF3·OEt2 to produce 6 in 79% yield. Glycosylation on OH-6 was
achieved with complete regioselectivity at low temperature and dilute
reactant concentration again employing imidate 4 as a glycosyl donor
and TMSOTf promotion to furnish the protected heptasaccharide 7 in
52% yield (Scheme 1). Phthalimide groups were removed by
microwave assisted aminolysis with diaminoethane and the inter-
mediate amine treated subsequently with acetic anhydride and sodium
methanolate to arrive at glycan 1 with four remaining benzyl groups in
the core chitobiose moiety as our key scaﬀold for enzymatic
diversiﬁcation. The synthesis of compound 2 followed an analogous
route which has been described earlier.42
C-Type Lectin Expression Cloning. Standard pUC57 plasmids
containing optimized synthetic human genes encoding human DC-
SIGN R ECD (amino acids 80−399) and LSECtin CRD (amino acids
162−292) designed for eﬃcient production in E. coli were
manufactured by GeneCust Europe. PCR ampliﬁcation using suitable
primers and restriction enzyme digestion were used to subclone DC-
SIGN R ECD and N-terminal 6-His tagged LSECtin CRD into the
pET30-b (Novagen) between the NdeI and HindIII restriction sites.
The sequencing of each construction was done by Genewiz.
Protein Expression and Puriﬁcation. The DC-SIGN extrac-
ellular domain (DC-SIGN ECD) was produced and puriﬁed as
previously described.58 DC-SIGNR ECD and L-SECtin CRD were
expressed in E. coli BL21(DE3) in 1 L of LB culture supplemented with
50 μg/mL kanamycin at 37 °C. Expression was induced by the addition
of 1 mM isopropyl 1-thio-D-galactopyranoside (IPTG) when the
culture had reached anA600nm of 0.8 andmaintained for 3 h. The protein
was expressed in the cytoplasm as inclusion bodies. Cells were
harvested by a 20 min centrifugation cycle at 5000g at 4 °C. The pellet
was resuspended in 30 mL of a solution containing 150 mM NaCl, 25
mM Tris-HCl at pH 8, and one antiprotease mixture tablet (Complete
EDTA free, Roche). Cells were disrupted by sonication and cell debris
eliminated by ultracentrifugation at 100 000g for 45 min at 4 °C with a
Beckman 45Ti rotor. The pellet was solubilized in 30 mL of 6 M
guanidine-HCl containing 25 mM Tris-HCl at pH 8, 150 mM NaCl,
and 0.01% (v/v) β-mercaptoethanol. The mixture was centrifuged at
100 000g for 45min at 4 °C, and the supernatant was diluted 5-fold with
1.25 M NaCl, 25 mM CaCl2, and 25 mM Tris-HCl or 200 mM Tris-
HCl at pH 8 (forDc-SIGNRor L-SECtin respectively) by slow addition
with stirring. The diluted mixture was dialyzed against 10 volumes of 25
mMTris-HCl at pH 8, 150 mMNaCl, and 4 mMCaCl2 (buﬀer A) with
three buﬀer changes. After dialysis, insoluble precipitate was removed
by centrifugation at 100 000g for 1 h at 4 °C.
The supernatant containing DC-SIGNR ECD was loaded onto a
mannan agarose column (Sigma) equilibrated with buﬀer A for
puriﬁcation by aﬃnity chromatography. After loading, DC-SIGNR
ECD was tightly bound to the column and eluted in the same buﬀer
without CaCl2 but supplemented with 1 mM EDTA (buﬀer B). This
step was followed by Size Exclusion Chromatography (SEC) using a
Superose 6 column equilibrated with buﬀer A. Fractions were analyzed
by SDS-PAGE (12%), and DC-SIGN R ECD containing fractions were
pooled and concentrated by ultraﬁltration (YM10 Amicon membrane
from Merck-Millipore).
The supernatant containing the His tagged LSECtin CRD was
loaded onto a HisTrap HP column (GE Heathcare) at 4 °C. Unbound
proteins were washed away with buﬀer A before LSECtin CRD was
eluted with buﬀer C (150 mM NaCl, 25 mM Tris-HCl at pH 8, 4 mM
CaCl2, 0.5 M imidazole). Eluted fractions were analyzed by SDS-PAGE
(15%), and the LSECtin CRD containing fractions were pooled and
concentrated by ultraﬁltration (YM10 Amicom membrane from
Merck-Millipore). Each construct was checked by N-terminal amino
acid sequencing and mass spectrometry.
Cy3 Labeling of DC-SIGN ECD, DC-SIGNR ECD, and LSECtin
CRD.A total of 150 μL of 10mgmL−1 solutions of DC-SIGNECD, 250
μL of 3.77 mg mL−1 solutions of DC-SIGNR ECD, and 1 mL of 0.5 mg
mL−1 solution of LSECtin CRD in 25 mM HEPES at pH 7.25 and 4
mM CaCl2 were prepared. Corresponding volumes (4.5, 3, and 2 μL,
respectively) of 10 mg mL−1 Cy3-NHS ester (GeneCopoeia) were
added to the DC-SIGN ECD, DC-SIGNR ECD, and LSECtin CRD
solutions individually, and the reactions were gently shaken at RT for 2
h and then at 4 °C for 4 h. Excess dye was removed by two dialyses (3.5k
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Z-lyser from Thermo Scientiﬁc) of 3 h against 25 mMTris at pH 8, 150
mM NaCl, and 4 mM CaCl2. The amount of attached Cy3 was
estimated spectrophotometrically based on the dye (ε550 150 000 cm
−1
M−1) and protein molar absorption coeﬃcients (ε280 DC-SIGN ECD
70 400 cm−1 M−1, ε280 DC-SIGNR ECD 60 890 cm
−1 M−1, ε280
LSECtin CRD 48 845 cm−1 M−1). The obtained degree of labeling
(DOL) was 0.95 for both DC-SIGN ECD and DC-SIGNR ECD and
0.2 for LSECtin CRD.
Microarray Preparation. Glycan microarrays were prepared as
previously described.33 Brieﬂy, ligand solutions (50 μM, 1.25 nL, ﬁve
drops, drop volume: 250 pL) in sodium phosphate buﬀer (300mM, pH
8.4, 0.005% Tween-20) were spatially arrayed employing a robotic
noncontact piezoelectric spotter (SciFLEXARRAYER S11, Scienion)
onto N-hydroxysuccinimide (NHS) activated glass slides (Nexterion
H, Schott AG). After printing, the slides were placed in a 75% humidity
chamber at 25 °C for 18 h. The remaining NHS groups were quenched
with 50 mM solution of ethanolamine in 50 mM sodium borate buﬀer,
at pH 9.0, for 1 h. The slides were washed with PBST (PBS solution
containing 0.05%Tween 20), PBS, and water. The slides were dried in a
slide spinner and stored at −20 °C until use.
Incubation with Monoclonal Antibodies.Monoclonal antibod-
ies (mAbs) were produced as previously described.49 Culture
supernatants containing IgM mAbs against Lex epitopes (128−4F9,
99−1G3, and 291−4D10) were diluted 1:200 in PBS containing 1%
(w/v) bovine serum albumin (BSA) and 0.01% (v/v) Tween-20. MAbs
solutions (200 μL per array) were used to incubate individual wells on a
glycan array slide at RT for 1 h. The slides were washed with PBST
(PBS containing 0.05% Tween-20) followed by PBS. Slides were then
incubated with antimouse IgM-555 (1:1000) in PBS containing 1%
BSA and 0.01% Tween-20 for 1 h in the dark. Arrays were washed from
unbound secondary antibodies with PBST, PBS, and water. Micro-
arrays were dried in a slide spinner, and ﬂuorescence measurements
were performed on a microarray scanner (Agilent G2565BA, Agilent
Technologies) at 10 μm resolution. Quantiﬁcation of ﬂuorescence was
performed by ProScanArray Express software (PerkinElmer) employ-
ing an adaptive circle quantiﬁcation method from 50 μm (minimum
spot diameter) to 300 μm (maximum spot diameter). Average RFU
values with local background subtraction of four spots and standard
deviation of the mean were reported using Microsoft Excel and
GraphPad Prism software.
Incubation with C-type Lectins. Cy3 labeled C-type lectins were
diluted in incubation buﬀer (25 mM Tris·HCl, 150 mM NaCl, 4 mM
CaCl2, pH 7.5 containing 0.5% bovine serum albumin (BSA), and
0.005% Tween-20). C-type lectin solutions (200 μL per array) were
used to incubate individual wells on a glycan array slide at 4 °C for 18 h.
Arrays were washed with incubation buﬀer without BSA and with water
and dried in a slide spinner. Fluorescence measurements and analysis
were performed as described above for monoclonal antibodies.
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